CHERRY HILL, N.J., April 30 /PRNewswire/ -- T.J. Harkins, President of TriMix Laboratories LLC, announced today that an abstract related to erectile dysfunction product, TriMix-gel(TM), will be presented at a moderated session of the American Urologic Association (AUA) annual meeting, May 20, 2008 in Orlando, FL. The study is entitled STUDIES WITH TRIMIX GEL IN MEN WHO FAILED PHOSPHODIESTERASE INHIBITORS.
The abstract evaluates TriMix-gel as an alternative for erectile dysfunction (ED) patients who failed treatment on oral tablets such as Viagra(R), Levitra(R) or Cialis(R), known as phosphodiesterase type 5 inhibitors (PDE5). The research was completed in Cherry Hill, New Jersey by Urologist Joel L. Marmar, MD and associates.
A test group of 42 patients who failed treatment with PDE5 oral agents were evaluated as to Erection Hardness Scores (EHS) and penile rigidity. The patients had various co-morbidities including high blood pressure, high cholesterol, diabetes and radical prostatectomy.
Statistically Significant Greater Erection Hardness Scores (EHS)
Dr. Marmar stated "The conclusions of the study indicate TriMix-gel may have several advantages over oral agents and intracavernous injections. Administration of the medicine is painless. Even without stimulation by a partner or erotic videos, TriMix-gel demonstrated statistically significant greater Erection Hardness Scores by the study group versus oral agents."
The abstract has been published in the Journal of Urology Supplement, J. Urol. 179 (4): 431, 2008. For more information on TriMix-gel visit http://www.trimixgel.com
TriMix-gel is prepared by a compounding pharmacy. The profession of
pharmacy has always been based on the patient-physician-pharmacist
relationship, known as the "Triad". Through this "Triad" relationship,
patient needs are determined by a physician, who chooses a treatment
regimen that may incl
|SOURCE TriMix Laboratories LLC|
Copyright©2008 PR Newswire.
All rights reserved